KLK3 and prostate cancer: The most updated results of this trial [25], in keeping with an earlier report [51], demonstrated statistically significant improvements in 10-year disease-specific mortality or death from prostate cancer (23% vs. 36%; p = .01), distant metastasis (35% vs. 47%; p = .006), disease-free survival (11% vs. 3%; p < .0001), and PSA failure (65% vs. 80%; p < .0001), all favoring the combination arm.